SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Mark A. Moyad, Prostate Cancer, 2016,

    CrossRef

  2. 2
    Craig R Ramsay, Temitope E Adewuyi, Joanne Gray, Jenni Hislop, Mark DF Shirley, Shalmini Jayakody, Graeme MacLennan, Cynthia Fraser, Sara MacLennan, Miriam Brazzelli, James N’Dow, Robert Pickard, Clare Robertson, Kieran Rothnie, Stephen P Rushton, Luke Vale, Thomas B Lam, Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation, Health Technology Assessment, 2015, 19, 49, 1

    CrossRef

  3. 3
    Anna C. Jones, Kresta S. Antillon, Shannon M. Jenkins, Sara N. Janos, Heidi N. Overton, Dor S. Shoshan, Edgar G. Fischer, Kristina A. Trujillo, Marco Bisoffi, Tanya V. Kalin, Prostate Field Cancerization: Deregulated Expression of Macrophage Inhibitory Cytokine 1 (MIC-1) and Platelet Derived Growth Factor A (PDGF-A) in Tumor Adjacent Tissue, PLOS ONE, 2015, 10, 3, e0119314

    CrossRef

  4. 4
    Tao Jiang, Changdong Zhou, Junlian Gu, Yanan Liu, Lijing Zhao, Wei Li, Guanjun Wang, Yang Li, Lu Cai, Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA, Cancer Letters, 2013, 337, 1, 133

    CrossRef

  5. 5
    Stephanie R. Earnshaw, Andrew P. Brogan, Cheryl L. McDade, Model-Based Cost-Effectiveness Analyses for Prostate Cancer Chemoprevention, PharmacoEconomics, 2013, 31, 4, 289

    CrossRef

  6. 6
    Gurdarshan S. Sandhu, Kenneth G. Nepple, Youssef S. Tanagho, Gerald L. Andriole, Prostate Cancer Chemoprevention, Seminars in Oncology, 2013, 40, 3, 276

    CrossRef

  7. 7
    Eric A. Klein, Ian M. Thompson, Chemoprevention of prostate cancer: an updated view, World Journal of Urology, 2012, 30, 2, 189

    CrossRef

  8. 8
    S B Stewart, C D Scales, J W Moul, S D Reed, Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?, Prostate Cancer and Prostatic Diseases, 2012, 15, 4, 380

    CrossRef

  9. 9
    Anna C. Jones, Kristina A. Trujillo, Genevieve K. Phillips, Trisha M. Fleet, Jaclyn K. Murton, Virginia Severns, Satyan K. Shah, Michael S. Davis, Anthony Y. Smith, Jeffrey K. Griffith, Edgar G. Fischer, Marco Bisoffi, Early growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization, The Prostate, 2012, 72, 11
  10. 10
    Faris Azzouni, James Mohler, Role of 5α-Reductase Inhibitors in Prostate Cancer Prevention and Treatment, Urology, 2012, 79, 6, 1197

    CrossRef

  11. 11
    Robert Abouassaly, Ian M. Thompson, Elizabeth A. Platz, Eric A. Klein, Campbell-Walsh Urology, 2012,

    CrossRef

  12. 12
    Robert J Hamilton, Stephen J Freedland, 5-α reductase inhibitors and prostate cancer prevention: where do we turn now?, BMC Medicine, 2011, 9, 1

    CrossRef

  13. 13
    Shelby D. Reed, Charles D. Scales, Suzanne B. Stewart, Jielin Sun, Judd W. Moul, Kevin A. Schulman, Jianfeng Xu, Effects of Family History and Genetic Polymorphism on the Cost-Effectiveness of Chemoprevention With Finasteride for Prostate Cancer, The Journal of Urology, 2011, 185, 3, 841

    CrossRef

  14. 14
    Jielin Sun, A. Karim Kader, Fang-Chi Hsu, Seong-Tae Kim, Yi Zhu, Aubrey R. Turner, Tao Jin, Zheng Zhang, Jan Adolfsson, Fredrik Wiklund, S. Lilly Zheng, William B. Isaacs, Henrik Grönberg, Jianfeng Xu, Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer, The Prostate, 2011, 71, 4
  15. 15
    S. Briancon, S. Boini, S. Bertrais, F. Guillemin, P. Galan, S. Hercberg, Long-term antioxidant supplementation has no effect on health-related quality of life: The randomized, double-blind, placebo-controlled, primary prevention SU.VI.MAX trial, International Journal of Epidemiology, 2011, 40, 6, 1605

    CrossRef

  16. You have free access to this content16
    Joan M. O'Connell, Susan Griffin, Overview of methods in economic analyses of behavioral interventions to promote oral health, Journal of Public Health Dentistry, 2011, 71,
  17. 17
    G. L. Gravina, F. Marampon, F. Petini, L. Biordi, D. Sherris, E. A. Jannini, V. Tombolini, C. Festuccia, The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells, Endocrine Related Cancer, 2011, 18, 4, 385

    CrossRef

  18. 18
    Andrew J. Stephenson, Robert Abouassaly, Eric A. Klein, Chemoprevention of Prostate Cancer, Urologic Clinics of North America, 2010, 37, 1, 11

    CrossRef

  19. 19
    Stephanie R. Earnshaw, Cheryl L. McDade, Libby K. Black, Christopher F. Bell, Michael W. Kattan, Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations, PharmacoEconomics, 2010, 28, 6, 489

    CrossRef

  20. 20
    Steven B Zeliadt, Scott D Ramsey, Cost–effectiveness of prostate cancer chemoprevention among high-risk men, Expert Review of Pharmacoeconomics & Outcomes Research, 2010, 10, 5, 505

    CrossRef

  21. 21
    Uzair B Chaudhary, Jeffrey S Turner, Finasteride, Expert Opinion on Drug Metabolism & Toxicology, 2010, 6, 7, 873

    CrossRef

  22. 22
    Andrew J. Vickers, Caroline J. Savage, Hans Lilja, Finasteride to Prevent Prostate Cancer: Should All Men or Only a High-Risk Subgroup Be Treated?, Journal of Clinical Oncology, 2010, 28, 7, 1112

    CrossRef

  23. 23
    Wesley M. White, Edward D. Kim, Prevention: Evolving role of 5-α reductase inhibitors in chemoprevention, Nature Reviews Clinical Oncology, 2010, 7, 9, 487

    CrossRef

  24. 24
    E. David Crawford, Gerald L. Andriole, Michael Marberger, Roger S. Rittmaster, Reduction in the Risk of Prostate Cancer: Future Directions After the Prostate Cancer Prevention Trial, Urology, 2010, 75, 3, 502

    CrossRef

  25. 25
    Ruchika Gutt, Nathan Tonlaar, Rangesh Kunnavakkam, Theodore Karrison, Ralph R. Weichselbaum, Stanley L. Liauw, Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy, Journal of Clinical Oncology, 2010, 28, 16, 2653

    CrossRef

  26. 26
    Seth A Strope, Gerald L Andriole, Update on chemoprevention for prostate cancer, Current Opinion in Urology, 2010, 20, 3, 194

    CrossRef

  27. 27
    Leonard G. Gomella, James Johannes, Edouard J. Trabulsi, Current Prostate Cancer Treatments: Effect on Quality of Life, Urology, 2009, 73, 5, S28

    CrossRef

  28. 28
    M. W. Pennington, C. R. Vernazza, P. Shackley, N. T. Armstrong, J. M. Whitworth, J. G. Steele, Evaluation of the cost-effectiveness of root canal treatment using conventional approaches versus replacement with an implant, International Endodontic Journal, 2009, 42, 10
  29. 29
    Roger S. Rittmaster, Neil E. Fleshner, Ian M. Thompson, Pharmacological Approaches to Reducing the Risk of Prostate Cancer, European Urology, 2009, 55, 5, 1064

    CrossRef

  30. 30
    Finasteride chemoprevention might be cost-effective in high-risk populations, Nature Clinical Practice Urology, 2008, 5, 5, 237

    CrossRef

  31. 31
    Cosimo De Nunzio, Roberto Miano, Alberto Trucchi, Enrico Finazzi Agrò, Andrea Tubaro, Finasteride for prostatic disease: an updated and comprehensive review, Expert Opinion on Drug Metabolism & Toxicology, 2008, 4, 12, 1561

    CrossRef

  32. 32
    Jamey A. Sarvis, Ian M. Thompson, Prostate cancer chemoprevention: Update of the prostate cancer prevention trial findings and implications for clinical practice, Current Oncology Reports, 2008, 10, 6, 529

    CrossRef

  33. 33
    Yair Lotan, Understanding Concepts Related to Health Economics in Urology,